Review



perindopril powder  (Santa Cruz Biotechnology)


Bioz Verified Symbol Santa Cruz Biotechnology is a verified supplier  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 93

    Structured Review

    Santa Cruz Biotechnology perindopril powder
    Figure 1. Effect of the different treatments on the daily food intake throughout the whole study (mean ± SD). a Significant compared to the control group; b Significant relative to the un- treated methotrexate group; c Significant relative to methotrexate group treated with <t>perindopril</t> 0.5 mg/kg/day; d Significant relative to methotrexate group treated with perindopril 1 mg/kg/day. MTX: methotrexate; PNP: perindopril.
    Perindopril Powder, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 93/100, based on 2 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/perindopril powder/product/Santa Cruz Biotechnology
    Average 93 stars, based on 2 article reviews
    perindopril powder - by Bioz Stars, 2026-02
    93/100 stars

    Images

    1) Product Images from "Repositioning Perindopril for Mitigation of Methotrexate-Induced Hepatotoxicity in Rats"

    Article Title: Repositioning Perindopril for Mitigation of Methotrexate-Induced Hepatotoxicity in Rats

    Journal: Pharmaceuticals

    doi: 10.3390/ph18030358

    Figure 1. Effect of the different treatments on the daily food intake throughout the whole study (mean ± SD). a Significant compared to the control group; b Significant relative to the un- treated methotrexate group; c Significant relative to methotrexate group treated with perindopril 0.5 mg/kg/day; d Significant relative to methotrexate group treated with perindopril 1 mg/kg/day. MTX: methotrexate; PNP: perindopril.
    Figure Legend Snippet: Figure 1. Effect of the different treatments on the daily food intake throughout the whole study (mean ± SD). a Significant compared to the control group; b Significant relative to the un- treated methotrexate group; c Significant relative to methotrexate group treated with perindopril 0.5 mg/kg/day; d Significant relative to methotrexate group treated with perindopril 1 mg/kg/day. MTX: methotrexate; PNP: perindopril.

    Techniques Used: Control

    Figure 2. Effect of the different doses of perindopril on the liver function tests in the animal groups treated with methotrexate (mean ± SD); * = p < 0.05, ** = p < 0.01, *** = p < 0.001; MTX: methotrexate; PNP: perindopril; ALT: alanine transaminase; AST: aspartate transaminase; ALP: alkaline phosphatase.
    Figure Legend Snippet: Figure 2. Effect of the different doses of perindopril on the liver function tests in the animal groups treated with methotrexate (mean ± SD); * = p < 0.05, ** = p < 0.01, *** = p < 0.001; MTX: methotrexate; PNP: perindopril; ALT: alanine transaminase; AST: aspartate transaminase; ALP: alkaline phosphatase.

    Techniques Used:

    Figure 3. Effect of the different doses of perindopril on the redox status of the hepatic tissues of the animal groups treated with methotrexate (mean ± SD); * = p < 0.05, ** = p < 0.01, *** = p < 0.001; MTX: methotrexate; PNP: perindopril; MDA: malondialdehyde; SOD: superoxide dismutase; TAC: total antioxidant capacity.
    Figure Legend Snippet: Figure 3. Effect of the different doses of perindopril on the redox status of the hepatic tissues of the animal groups treated with methotrexate (mean ± SD); * = p < 0.05, ** = p < 0.01, *** = p < 0.001; MTX: methotrexate; PNP: perindopril; MDA: malondialdehyde; SOD: superoxide dismutase; TAC: total antioxidant capacity.

    Techniques Used:

    Figure 4. Effect of the different doses of perindopril on sirtuin-1 and peroxisome proliferator- activated receptor gamma levels in the hepatic tissues of the animal groups treated with methotrexate (mean ± SD); ** = p < 0.01, *** = p < 0.001; MTX: methotrexate; PNP: perindopril; SIRT1: sirtuin-1; PPAR-γ: peroxisome proliferator-activated receptor gamma.
    Figure Legend Snippet: Figure 4. Effect of the different doses of perindopril on sirtuin-1 and peroxisome proliferator- activated receptor gamma levels in the hepatic tissues of the animal groups treated with methotrexate (mean ± SD); ** = p < 0.01, *** = p < 0.001; MTX: methotrexate; PNP: perindopril; SIRT1: sirtuin-1; PPAR-γ: peroxisome proliferator-activated receptor gamma.

    Techniques Used:

    Figure 5. Effect of the different doses of perindopril on KEAP1, Nrf2, and HO-1 content of the hepatic tissues of the animal groups treated with methotrexate (mean ± SD); * = p < 0.05, ** = p < 0.01, *** = p < 0.001; MTX: methotrexate; PNP: perindopril; KEAP1: Kelch-like ECH-associated protein 1; Nrf2: nuclear factor erythroid 2-related factor 2; HO-1: heme oxygenase-1.
    Figure Legend Snippet: Figure 5. Effect of the different doses of perindopril on KEAP1, Nrf2, and HO-1 content of the hepatic tissues of the animal groups treated with methotrexate (mean ± SD); * = p < 0.05, ** = p < 0.01, *** = p < 0.001; MTX: methotrexate; PNP: perindopril; KEAP1: Kelch-like ECH-associated protein 1; Nrf2: nuclear factor erythroid 2-related factor 2; HO-1: heme oxygenase-1.

    Techniques Used:

    Figure 5 shows the effect of the different treatments on KEAP1/Nrf2/HO-1 signaling in the hepatic tissues. The significant increase in tissue KEAP1 levels associated with the significant decline in the hepatic tissue content of Nrf2 and HO-1 induced by methotrexate injection was dose-dependently mitigated with the administration of perindopril. This clarifies the role played by KEAP1 in the regulation of Nrf2/HO-1 signaling.
    Figure Legend Snippet: Figure 5 shows the effect of the different treatments on KEAP1/Nrf2/HO-1 signaling in the hepatic tissues. The significant increase in tissue KEAP1 levels associated with the significant decline in the hepatic tissue content of Nrf2 and HO-1 induced by methotrexate injection was dose-dependently mitigated with the administration of perindopril. This clarifies the role played by KEAP1 in the regulation of Nrf2/HO-1 signaling.

    Techniques Used: Injection

    Figure 6. Effect of the different doses of perindopril on IL-1β, IL-6, MCP-1, and TNF-α levels in the hepatic tissues of the animal groups treated with methotrexate (mean ± SD); *** = p < 0.001; MTX: methotrexate; PNP: perindopril; IL-1β: interleukin 1-beta; MCP-1: monocyte chemoattractant protein 1; TNF-α: tumor necrosis factor-alpha.
    Figure Legend Snippet: Figure 6. Effect of the different doses of perindopril on IL-1β, IL-6, MCP-1, and TNF-α levels in the hepatic tissues of the animal groups treated with methotrexate (mean ± SD); *** = p < 0.001; MTX: methotrexate; PNP: perindopril; IL-1β: interleukin 1-beta; MCP-1: monocyte chemoattractant protein 1; TNF-α: tumor necrosis factor-alpha.

    Techniques Used:

    Figure 7. Effect of the different doses of perindopril on HMGB1/RAGE/NF-κB axis in the hepatic tissues of the animal groups treated with methotrexate (mean ± SD); ns = non-significant, ** = p < 0.01, *** = p < 0.001; MTX: methotrexate; PNP: perindopril; HMGB1: High-Mobility Group Box 1; RAGE: receptors for advanced glycation end products; NF-κB: nuclear factor kappa B.
    Figure Legend Snippet: Figure 7. Effect of the different doses of perindopril on HMGB1/RAGE/NF-κB axis in the hepatic tissues of the animal groups treated with methotrexate (mean ± SD); ns = non-significant, ** = p < 0.01, *** = p < 0.001; MTX: methotrexate; PNP: perindopril; HMGB1: High-Mobility Group Box 1; RAGE: receptors for advanced glycation end products; NF-κB: nuclear factor kappa B.

    Techniques Used:

    Figure 8. Effect of the different doses of perindopril on phospho-mTOR, total AMPK, and LC3-II levels in the hepatic tissues of the animal groups treated with methotrexate (mean ± SD); ns = non- significant, * = p < 0.05, ** = p < 0.01, *** = p < 0.001; MTX: methotrexate; PNP: perindopril; phospho- mTOR: phosphorylated mammalian target of rapamycin; AMPK: adenosine monophosphate- activated protein kinase; LC3-II: microtubule-associated protein light chain 3.
    Figure Legend Snippet: Figure 8. Effect of the different doses of perindopril on phospho-mTOR, total AMPK, and LC3-II levels in the hepatic tissues of the animal groups treated with methotrexate (mean ± SD); ns = non- significant, * = p < 0.05, ** = p < 0.01, *** = p < 0.001; MTX: methotrexate; PNP: perindopril; phospho- mTOR: phosphorylated mammalian target of rapamycin; AMPK: adenosine monophosphate- activated protein kinase; LC3-II: microtubule-associated protein light chain 3.

    Techniques Used:

    Figure 9. Effect of the different doses of perindopril on hydroxyproline, MMP-3, and MMP-9 in the hepatic tissues of the animal groups treated with methotrexate (mean ± SD); ns = non-significant, ** = p < 0.01, *** = p < 0.001; MTX: methotrexate; PNP: perindopril; MMP: matrix metalloproteinase.
    Figure Legend Snippet: Figure 9. Effect of the different doses of perindopril on hydroxyproline, MMP-3, and MMP-9 in the hepatic tissues of the animal groups treated with methotrexate (mean ± SD); ns = non-significant, ** = p < 0.01, *** = p < 0.001; MTX: methotrexate; PNP: perindopril; MMP: matrix metalloproteinase.

    Techniques Used:

    Figure 10. Hematoxylin and eosin-stained sections of the liver from (A) the control group showing the characteristic hexagonal classic hepatic lobules with central veins (CV) at the center and portal tracts (PT) at the periphery. The polygonal hepatocytes are arranged in cords separated by blood sinusoids (S) (×100); (B) methotrexate group exhibiting loss of normal hepatic architecture with dilated and markedly congested central vein (CV) and portal venules (PV) with diffuse perivascular, periportal, and interstitial inflammatory cellular infiltration (I). The central parts of the blood sinusoids (S) appear dilated in some regions with focal areas of hepatic necrosis (Thin arrows) (×100); (C) Portal tract of methotrexate group showing dilated congested portal venules (PV) and hepatic arterioles (HA) with proliferation of bile ductules (BD) (Thick arrows). Also, scattered areas of inflammatory cellular infiltration (I) are seen in the portal area (×400); (D) methotrexate group treated with a small dose of perindopril revealing a significant improvement in the hepatic architecture with cords of normal hepatocytes that surround a mildly dilated central vein (CV). Some hepatic sinusoids appear mildly dilated (S) with scanty areas of hepatic necrosis (Thin arrows) and inflammatory cellular infiltration (I) (×100); (E) methotrexate group treated with a moderate dose of perindopril showing minimal dilatation of the central veins which are surrounded by cords of hepatocytes with acidophilic cytoplasm and vesicular nuclei. Some of the blood sinusoids (S) appear dilated with minimal inflammatory cellular infiltration (I) (×100); (F) methotrexate group treated with a large dose of perindopril exhibiting restoration of the normal hepatic histomorphic structure with appearance of the classic hexagonal hepatic lobules with apparently normal central veins (CV) and portal tracts with minimal congestion of the portal venules (PV) (×100).
    Figure Legend Snippet: Figure 10. Hematoxylin and eosin-stained sections of the liver from (A) the control group showing the characteristic hexagonal classic hepatic lobules with central veins (CV) at the center and portal tracts (PT) at the periphery. The polygonal hepatocytes are arranged in cords separated by blood sinusoids (S) (×100); (B) methotrexate group exhibiting loss of normal hepatic architecture with dilated and markedly congested central vein (CV) and portal venules (PV) with diffuse perivascular, periportal, and interstitial inflammatory cellular infiltration (I). The central parts of the blood sinusoids (S) appear dilated in some regions with focal areas of hepatic necrosis (Thin arrows) (×100); (C) Portal tract of methotrexate group showing dilated congested portal venules (PV) and hepatic arterioles (HA) with proliferation of bile ductules (BD) (Thick arrows). Also, scattered areas of inflammatory cellular infiltration (I) are seen in the portal area (×400); (D) methotrexate group treated with a small dose of perindopril revealing a significant improvement in the hepatic architecture with cords of normal hepatocytes that surround a mildly dilated central vein (CV). Some hepatic sinusoids appear mildly dilated (S) with scanty areas of hepatic necrosis (Thin arrows) and inflammatory cellular infiltration (I) (×100); (E) methotrexate group treated with a moderate dose of perindopril showing minimal dilatation of the central veins which are surrounded by cords of hepatocytes with acidophilic cytoplasm and vesicular nuclei. Some of the blood sinusoids (S) appear dilated with minimal inflammatory cellular infiltration (I) (×100); (F) methotrexate group treated with a large dose of perindopril exhibiting restoration of the normal hepatic histomorphic structure with appearance of the classic hexagonal hepatic lobules with apparently normal central veins (CV) and portal tracts with minimal congestion of the portal venules (PV) (×100).

    Techniques Used: Staining, Control

    Figure 11. Hepatic tissue sections of immunohistochemical staining of cleaved caspase 3 in (A) The control group clarifying minimal positive immunostaining for cleaved caspase 3; (B) The group that received methotrexate alone exhibiting strongly positive immunostaining for cleaved caspase 3; (C–E) Methotrexate-injected groups treated with small, moderate, and large doses of perindopril, respectively, showing mild positive immunostaining for cleaved caspase 3; (F) Quantitative represen- tation of the percentage of cleaved caspase 3 immune expression in the different studied groups (% of the control); * = p < 0.05, *** = p < 0.001; MTX: methotrexate; PNP: perindopril.
    Figure Legend Snippet: Figure 11. Hepatic tissue sections of immunohistochemical staining of cleaved caspase 3 in (A) The control group clarifying minimal positive immunostaining for cleaved caspase 3; (B) The group that received methotrexate alone exhibiting strongly positive immunostaining for cleaved caspase 3; (C–E) Methotrexate-injected groups treated with small, moderate, and large doses of perindopril, respectively, showing mild positive immunostaining for cleaved caspase 3; (F) Quantitative represen- tation of the percentage of cleaved caspase 3 immune expression in the different studied groups (% of the control); * = p < 0.05, *** = p < 0.001; MTX: methotrexate; PNP: perindopril.

    Techniques Used: Immunohistochemical staining, Staining, Control, Immunostaining, Injection, Expressing

    Figure 12. Electron micrographs of ultrathin sections in the liver from animals of (A) the control group showing normal architecture of the hepatic tissues. The nuclei (N) appeared spherical with regular outlines with a small amount of heterochromatin in the peripheral regions and a large central amount of euchromatin and prominent nucleolus. The cytoplasm of the hepatocytes contains abundant mitochondria (Arrow) with well-developed cristae and the rough endoplasmic reticulum (RER) consists of closely packed parallel and flattened cisternae (Arrowhead); (B,C) methotrexate- treated group showing shrunken irregular nucleus with dispersed chromatin (N) and reduced number of the mitochondria with disrupted cristae (Arrow). The cisternae of the rough endoplasmic reticulum (RER) of the hepatocytes are fragmented (Arrowhead) with extensive fat droplets (F) and marked cytoplasmic vacuolation (V); (D) methotrexate group treated with a small dose of perindopril revealing irregular nucleus with preserved nucleolus (N). There is a mild increase in the number of the viable mitochondria with mild disrupted cristae (Arrow), partly preserved cisternae of the rough endoplasmic reticulum (Arrowhead), and small number of fat droplets could be observed (F); (E) methotrexate group treated with a moderate dose of perindopril exhibiting a spherical nucleus with regular wall and preserved nucleolus (N). There is moderate increase in the number of the mitochondria with mild disrupted cristae (Arrow) with mild disruption and wide separation of the cisternae of the rough endoplasmic reticulum (Arrowhead); (F) methotrexate group treated with a large dose of perindopril showing a normal spherical nucleus with intact regular walls and preserved nucleolus (N). The mitochondria are abundant with preserved cristae (Arrow) and the rough endoplasmic reticulum cisternae appear nearly normal with mild dilatation (Arrowhead).
    Figure Legend Snippet: Figure 12. Electron micrographs of ultrathin sections in the liver from animals of (A) the control group showing normal architecture of the hepatic tissues. The nuclei (N) appeared spherical with regular outlines with a small amount of heterochromatin in the peripheral regions and a large central amount of euchromatin and prominent nucleolus. The cytoplasm of the hepatocytes contains abundant mitochondria (Arrow) with well-developed cristae and the rough endoplasmic reticulum (RER) consists of closely packed parallel and flattened cisternae (Arrowhead); (B,C) methotrexate- treated group showing shrunken irregular nucleus with dispersed chromatin (N) and reduced number of the mitochondria with disrupted cristae (Arrow). The cisternae of the rough endoplasmic reticulum (RER) of the hepatocytes are fragmented (Arrowhead) with extensive fat droplets (F) and marked cytoplasmic vacuolation (V); (D) methotrexate group treated with a small dose of perindopril revealing irregular nucleus with preserved nucleolus (N). There is a mild increase in the number of the viable mitochondria with mild disrupted cristae (Arrow), partly preserved cisternae of the rough endoplasmic reticulum (Arrowhead), and small number of fat droplets could be observed (F); (E) methotrexate group treated with a moderate dose of perindopril exhibiting a spherical nucleus with regular wall and preserved nucleolus (N). There is moderate increase in the number of the mitochondria with mild disrupted cristae (Arrow) with mild disruption and wide separation of the cisternae of the rough endoplasmic reticulum (Arrowhead); (F) methotrexate group treated with a large dose of perindopril showing a normal spherical nucleus with intact regular walls and preserved nucleolus (N). The mitochondria are abundant with preserved cristae (Arrow) and the rough endoplasmic reticulum cisternae appear nearly normal with mild dilatation (Arrowhead).

    Techniques Used: Control, Disruption

    Figure 13. The mechanisms by which perindopril mitigates methotrexate-induced hepatotoxicity (This artwork was constructed using Reactome icon library and Smart Art Servier items).
    Figure Legend Snippet: Figure 13. The mechanisms by which perindopril mitigates methotrexate-induced hepatotoxicity (This artwork was constructed using Reactome icon library and Smart Art Servier items).

    Techniques Used: Construct



    Similar Products

    93
    Santa Cruz Biotechnology perindopril powder
    Figure 1. Effect of the different treatments on the daily food intake throughout the whole study (mean ± SD). a Significant compared to the control group; b Significant relative to the un- treated methotrexate group; c Significant relative to methotrexate group treated with <t>perindopril</t> 0.5 mg/kg/day; d Significant relative to methotrexate group treated with perindopril 1 mg/kg/day. MTX: methotrexate; PNP: perindopril.
    Perindopril Powder, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/perindopril powder/product/Santa Cruz Biotechnology
    Average 93 stars, based on 1 article reviews
    perindopril powder - by Bioz Stars, 2026-02
    93/100 stars
      Buy from Supplier

    90
    Pharmachem Laboratories Inc perindopril erbumine powder
    Figure 1. Effect of the different treatments on the daily food intake throughout the whole study (mean ± SD). a Significant compared to the control group; b Significant relative to the un- treated methotrexate group; c Significant relative to methotrexate group treated with <t>perindopril</t> 0.5 mg/kg/day; d Significant relative to methotrexate group treated with perindopril 1 mg/kg/day. MTX: methotrexate; PNP: perindopril.
    Perindopril Erbumine Powder, supplied by Pharmachem Laboratories Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/perindopril erbumine powder/product/Pharmachem Laboratories Inc
    Average 90 stars, based on 1 article reviews
    perindopril erbumine powder - by Bioz Stars, 2026-02
    90/100 stars
      Buy from Supplier

    Image Search Results


    Figure 1. Effect of the different treatments on the daily food intake throughout the whole study (mean ± SD). a Significant compared to the control group; b Significant relative to the un- treated methotrexate group; c Significant relative to methotrexate group treated with perindopril 0.5 mg/kg/day; d Significant relative to methotrexate group treated with perindopril 1 mg/kg/day. MTX: methotrexate; PNP: perindopril.

    Journal: Pharmaceuticals

    Article Title: Repositioning Perindopril for Mitigation of Methotrexate-Induced Hepatotoxicity in Rats

    doi: 10.3390/ph18030358

    Figure Lengend Snippet: Figure 1. Effect of the different treatments on the daily food intake throughout the whole study (mean ± SD). a Significant compared to the control group; b Significant relative to the un- treated methotrexate group; c Significant relative to methotrexate group treated with perindopril 0.5 mg/kg/day; d Significant relative to methotrexate group treated with perindopril 1 mg/kg/day. MTX: methotrexate; PNP: perindopril.

    Article Snippet: Perindopril powder was supplied by Santa Cruz Biotechnology, Inc., Dallas, TX, USA (Catalog # sc205799A; CAS No. 82834-16-0).

    Techniques: Control

    Figure 2. Effect of the different doses of perindopril on the liver function tests in the animal groups treated with methotrexate (mean ± SD); * = p < 0.05, ** = p < 0.01, *** = p < 0.001; MTX: methotrexate; PNP: perindopril; ALT: alanine transaminase; AST: aspartate transaminase; ALP: alkaline phosphatase.

    Journal: Pharmaceuticals

    Article Title: Repositioning Perindopril for Mitigation of Methotrexate-Induced Hepatotoxicity in Rats

    doi: 10.3390/ph18030358

    Figure Lengend Snippet: Figure 2. Effect of the different doses of perindopril on the liver function tests in the animal groups treated with methotrexate (mean ± SD); * = p < 0.05, ** = p < 0.01, *** = p < 0.001; MTX: methotrexate; PNP: perindopril; ALT: alanine transaminase; AST: aspartate transaminase; ALP: alkaline phosphatase.

    Article Snippet: Perindopril powder was supplied by Santa Cruz Biotechnology, Inc., Dallas, TX, USA (Catalog # sc205799A; CAS No. 82834-16-0).

    Techniques:

    Figure 3. Effect of the different doses of perindopril on the redox status of the hepatic tissues of the animal groups treated with methotrexate (mean ± SD); * = p < 0.05, ** = p < 0.01, *** = p < 0.001; MTX: methotrexate; PNP: perindopril; MDA: malondialdehyde; SOD: superoxide dismutase; TAC: total antioxidant capacity.

    Journal: Pharmaceuticals

    Article Title: Repositioning Perindopril for Mitigation of Methotrexate-Induced Hepatotoxicity in Rats

    doi: 10.3390/ph18030358

    Figure Lengend Snippet: Figure 3. Effect of the different doses of perindopril on the redox status of the hepatic tissues of the animal groups treated with methotrexate (mean ± SD); * = p < 0.05, ** = p < 0.01, *** = p < 0.001; MTX: methotrexate; PNP: perindopril; MDA: malondialdehyde; SOD: superoxide dismutase; TAC: total antioxidant capacity.

    Article Snippet: Perindopril powder was supplied by Santa Cruz Biotechnology, Inc., Dallas, TX, USA (Catalog # sc205799A; CAS No. 82834-16-0).

    Techniques:

    Figure 4. Effect of the different doses of perindopril on sirtuin-1 and peroxisome proliferator- activated receptor gamma levels in the hepatic tissues of the animal groups treated with methotrexate (mean ± SD); ** = p < 0.01, *** = p < 0.001; MTX: methotrexate; PNP: perindopril; SIRT1: sirtuin-1; PPAR-γ: peroxisome proliferator-activated receptor gamma.

    Journal: Pharmaceuticals

    Article Title: Repositioning Perindopril for Mitigation of Methotrexate-Induced Hepatotoxicity in Rats

    doi: 10.3390/ph18030358

    Figure Lengend Snippet: Figure 4. Effect of the different doses of perindopril on sirtuin-1 and peroxisome proliferator- activated receptor gamma levels in the hepatic tissues of the animal groups treated with methotrexate (mean ± SD); ** = p < 0.01, *** = p < 0.001; MTX: methotrexate; PNP: perindopril; SIRT1: sirtuin-1; PPAR-γ: peroxisome proliferator-activated receptor gamma.

    Article Snippet: Perindopril powder was supplied by Santa Cruz Biotechnology, Inc., Dallas, TX, USA (Catalog # sc205799A; CAS No. 82834-16-0).

    Techniques:

    Figure 5. Effect of the different doses of perindopril on KEAP1, Nrf2, and HO-1 content of the hepatic tissues of the animal groups treated with methotrexate (mean ± SD); * = p < 0.05, ** = p < 0.01, *** = p < 0.001; MTX: methotrexate; PNP: perindopril; KEAP1: Kelch-like ECH-associated protein 1; Nrf2: nuclear factor erythroid 2-related factor 2; HO-1: heme oxygenase-1.

    Journal: Pharmaceuticals

    Article Title: Repositioning Perindopril for Mitigation of Methotrexate-Induced Hepatotoxicity in Rats

    doi: 10.3390/ph18030358

    Figure Lengend Snippet: Figure 5. Effect of the different doses of perindopril on KEAP1, Nrf2, and HO-1 content of the hepatic tissues of the animal groups treated with methotrexate (mean ± SD); * = p < 0.05, ** = p < 0.01, *** = p < 0.001; MTX: methotrexate; PNP: perindopril; KEAP1: Kelch-like ECH-associated protein 1; Nrf2: nuclear factor erythroid 2-related factor 2; HO-1: heme oxygenase-1.

    Article Snippet: Perindopril powder was supplied by Santa Cruz Biotechnology, Inc., Dallas, TX, USA (Catalog # sc205799A; CAS No. 82834-16-0).

    Techniques:

    Figure 5 shows the effect of the different treatments on KEAP1/Nrf2/HO-1 signaling in the hepatic tissues. The significant increase in tissue KEAP1 levels associated with the significant decline in the hepatic tissue content of Nrf2 and HO-1 induced by methotrexate injection was dose-dependently mitigated with the administration of perindopril. This clarifies the role played by KEAP1 in the regulation of Nrf2/HO-1 signaling.

    Journal: Pharmaceuticals

    Article Title: Repositioning Perindopril for Mitigation of Methotrexate-Induced Hepatotoxicity in Rats

    doi: 10.3390/ph18030358

    Figure Lengend Snippet: Figure 5 shows the effect of the different treatments on KEAP1/Nrf2/HO-1 signaling in the hepatic tissues. The significant increase in tissue KEAP1 levels associated with the significant decline in the hepatic tissue content of Nrf2 and HO-1 induced by methotrexate injection was dose-dependently mitigated with the administration of perindopril. This clarifies the role played by KEAP1 in the regulation of Nrf2/HO-1 signaling.

    Article Snippet: Perindopril powder was supplied by Santa Cruz Biotechnology, Inc., Dallas, TX, USA (Catalog # sc205799A; CAS No. 82834-16-0).

    Techniques: Injection

    Figure 6. Effect of the different doses of perindopril on IL-1β, IL-6, MCP-1, and TNF-α levels in the hepatic tissues of the animal groups treated with methotrexate (mean ± SD); *** = p < 0.001; MTX: methotrexate; PNP: perindopril; IL-1β: interleukin 1-beta; MCP-1: monocyte chemoattractant protein 1; TNF-α: tumor necrosis factor-alpha.

    Journal: Pharmaceuticals

    Article Title: Repositioning Perindopril for Mitigation of Methotrexate-Induced Hepatotoxicity in Rats

    doi: 10.3390/ph18030358

    Figure Lengend Snippet: Figure 6. Effect of the different doses of perindopril on IL-1β, IL-6, MCP-1, and TNF-α levels in the hepatic tissues of the animal groups treated with methotrexate (mean ± SD); *** = p < 0.001; MTX: methotrexate; PNP: perindopril; IL-1β: interleukin 1-beta; MCP-1: monocyte chemoattractant protein 1; TNF-α: tumor necrosis factor-alpha.

    Article Snippet: Perindopril powder was supplied by Santa Cruz Biotechnology, Inc., Dallas, TX, USA (Catalog # sc205799A; CAS No. 82834-16-0).

    Techniques:

    Figure 7. Effect of the different doses of perindopril on HMGB1/RAGE/NF-κB axis in the hepatic tissues of the animal groups treated with methotrexate (mean ± SD); ns = non-significant, ** = p < 0.01, *** = p < 0.001; MTX: methotrexate; PNP: perindopril; HMGB1: High-Mobility Group Box 1; RAGE: receptors for advanced glycation end products; NF-κB: nuclear factor kappa B.

    Journal: Pharmaceuticals

    Article Title: Repositioning Perindopril for Mitigation of Methotrexate-Induced Hepatotoxicity in Rats

    doi: 10.3390/ph18030358

    Figure Lengend Snippet: Figure 7. Effect of the different doses of perindopril on HMGB1/RAGE/NF-κB axis in the hepatic tissues of the animal groups treated with methotrexate (mean ± SD); ns = non-significant, ** = p < 0.01, *** = p < 0.001; MTX: methotrexate; PNP: perindopril; HMGB1: High-Mobility Group Box 1; RAGE: receptors for advanced glycation end products; NF-κB: nuclear factor kappa B.

    Article Snippet: Perindopril powder was supplied by Santa Cruz Biotechnology, Inc., Dallas, TX, USA (Catalog # sc205799A; CAS No. 82834-16-0).

    Techniques:

    Figure 8. Effect of the different doses of perindopril on phospho-mTOR, total AMPK, and LC3-II levels in the hepatic tissues of the animal groups treated with methotrexate (mean ± SD); ns = non- significant, * = p < 0.05, ** = p < 0.01, *** = p < 0.001; MTX: methotrexate; PNP: perindopril; phospho- mTOR: phosphorylated mammalian target of rapamycin; AMPK: adenosine monophosphate- activated protein kinase; LC3-II: microtubule-associated protein light chain 3.

    Journal: Pharmaceuticals

    Article Title: Repositioning Perindopril for Mitigation of Methotrexate-Induced Hepatotoxicity in Rats

    doi: 10.3390/ph18030358

    Figure Lengend Snippet: Figure 8. Effect of the different doses of perindopril on phospho-mTOR, total AMPK, and LC3-II levels in the hepatic tissues of the animal groups treated with methotrexate (mean ± SD); ns = non- significant, * = p < 0.05, ** = p < 0.01, *** = p < 0.001; MTX: methotrexate; PNP: perindopril; phospho- mTOR: phosphorylated mammalian target of rapamycin; AMPK: adenosine monophosphate- activated protein kinase; LC3-II: microtubule-associated protein light chain 3.

    Article Snippet: Perindopril powder was supplied by Santa Cruz Biotechnology, Inc., Dallas, TX, USA (Catalog # sc205799A; CAS No. 82834-16-0).

    Techniques:

    Figure 9. Effect of the different doses of perindopril on hydroxyproline, MMP-3, and MMP-9 in the hepatic tissues of the animal groups treated with methotrexate (mean ± SD); ns = non-significant, ** = p < 0.01, *** = p < 0.001; MTX: methotrexate; PNP: perindopril; MMP: matrix metalloproteinase.

    Journal: Pharmaceuticals

    Article Title: Repositioning Perindopril for Mitigation of Methotrexate-Induced Hepatotoxicity in Rats

    doi: 10.3390/ph18030358

    Figure Lengend Snippet: Figure 9. Effect of the different doses of perindopril on hydroxyproline, MMP-3, and MMP-9 in the hepatic tissues of the animal groups treated with methotrexate (mean ± SD); ns = non-significant, ** = p < 0.01, *** = p < 0.001; MTX: methotrexate; PNP: perindopril; MMP: matrix metalloproteinase.

    Article Snippet: Perindopril powder was supplied by Santa Cruz Biotechnology, Inc., Dallas, TX, USA (Catalog # sc205799A; CAS No. 82834-16-0).

    Techniques:

    Figure 10. Hematoxylin and eosin-stained sections of the liver from (A) the control group showing the characteristic hexagonal classic hepatic lobules with central veins (CV) at the center and portal tracts (PT) at the periphery. The polygonal hepatocytes are arranged in cords separated by blood sinusoids (S) (×100); (B) methotrexate group exhibiting loss of normal hepatic architecture with dilated and markedly congested central vein (CV) and portal venules (PV) with diffuse perivascular, periportal, and interstitial inflammatory cellular infiltration (I). The central parts of the blood sinusoids (S) appear dilated in some regions with focal areas of hepatic necrosis (Thin arrows) (×100); (C) Portal tract of methotrexate group showing dilated congested portal venules (PV) and hepatic arterioles (HA) with proliferation of bile ductules (BD) (Thick arrows). Also, scattered areas of inflammatory cellular infiltration (I) are seen in the portal area (×400); (D) methotrexate group treated with a small dose of perindopril revealing a significant improvement in the hepatic architecture with cords of normal hepatocytes that surround a mildly dilated central vein (CV). Some hepatic sinusoids appear mildly dilated (S) with scanty areas of hepatic necrosis (Thin arrows) and inflammatory cellular infiltration (I) (×100); (E) methotrexate group treated with a moderate dose of perindopril showing minimal dilatation of the central veins which are surrounded by cords of hepatocytes with acidophilic cytoplasm and vesicular nuclei. Some of the blood sinusoids (S) appear dilated with minimal inflammatory cellular infiltration (I) (×100); (F) methotrexate group treated with a large dose of perindopril exhibiting restoration of the normal hepatic histomorphic structure with appearance of the classic hexagonal hepatic lobules with apparently normal central veins (CV) and portal tracts with minimal congestion of the portal venules (PV) (×100).

    Journal: Pharmaceuticals

    Article Title: Repositioning Perindopril for Mitigation of Methotrexate-Induced Hepatotoxicity in Rats

    doi: 10.3390/ph18030358

    Figure Lengend Snippet: Figure 10. Hematoxylin and eosin-stained sections of the liver from (A) the control group showing the characteristic hexagonal classic hepatic lobules with central veins (CV) at the center and portal tracts (PT) at the periphery. The polygonal hepatocytes are arranged in cords separated by blood sinusoids (S) (×100); (B) methotrexate group exhibiting loss of normal hepatic architecture with dilated and markedly congested central vein (CV) and portal venules (PV) with diffuse perivascular, periportal, and interstitial inflammatory cellular infiltration (I). The central parts of the blood sinusoids (S) appear dilated in some regions with focal areas of hepatic necrosis (Thin arrows) (×100); (C) Portal tract of methotrexate group showing dilated congested portal venules (PV) and hepatic arterioles (HA) with proliferation of bile ductules (BD) (Thick arrows). Also, scattered areas of inflammatory cellular infiltration (I) are seen in the portal area (×400); (D) methotrexate group treated with a small dose of perindopril revealing a significant improvement in the hepatic architecture with cords of normal hepatocytes that surround a mildly dilated central vein (CV). Some hepatic sinusoids appear mildly dilated (S) with scanty areas of hepatic necrosis (Thin arrows) and inflammatory cellular infiltration (I) (×100); (E) methotrexate group treated with a moderate dose of perindopril showing minimal dilatation of the central veins which are surrounded by cords of hepatocytes with acidophilic cytoplasm and vesicular nuclei. Some of the blood sinusoids (S) appear dilated with minimal inflammatory cellular infiltration (I) (×100); (F) methotrexate group treated with a large dose of perindopril exhibiting restoration of the normal hepatic histomorphic structure with appearance of the classic hexagonal hepatic lobules with apparently normal central veins (CV) and portal tracts with minimal congestion of the portal venules (PV) (×100).

    Article Snippet: Perindopril powder was supplied by Santa Cruz Biotechnology, Inc., Dallas, TX, USA (Catalog # sc205799A; CAS No. 82834-16-0).

    Techniques: Staining, Control

    Figure 11. Hepatic tissue sections of immunohistochemical staining of cleaved caspase 3 in (A) The control group clarifying minimal positive immunostaining for cleaved caspase 3; (B) The group that received methotrexate alone exhibiting strongly positive immunostaining for cleaved caspase 3; (C–E) Methotrexate-injected groups treated with small, moderate, and large doses of perindopril, respectively, showing mild positive immunostaining for cleaved caspase 3; (F) Quantitative represen- tation of the percentage of cleaved caspase 3 immune expression in the different studied groups (% of the control); * = p < 0.05, *** = p < 0.001; MTX: methotrexate; PNP: perindopril.

    Journal: Pharmaceuticals

    Article Title: Repositioning Perindopril for Mitigation of Methotrexate-Induced Hepatotoxicity in Rats

    doi: 10.3390/ph18030358

    Figure Lengend Snippet: Figure 11. Hepatic tissue sections of immunohistochemical staining of cleaved caspase 3 in (A) The control group clarifying minimal positive immunostaining for cleaved caspase 3; (B) The group that received methotrexate alone exhibiting strongly positive immunostaining for cleaved caspase 3; (C–E) Methotrexate-injected groups treated with small, moderate, and large doses of perindopril, respectively, showing mild positive immunostaining for cleaved caspase 3; (F) Quantitative represen- tation of the percentage of cleaved caspase 3 immune expression in the different studied groups (% of the control); * = p < 0.05, *** = p < 0.001; MTX: methotrexate; PNP: perindopril.

    Article Snippet: Perindopril powder was supplied by Santa Cruz Biotechnology, Inc., Dallas, TX, USA (Catalog # sc205799A; CAS No. 82834-16-0).

    Techniques: Immunohistochemical staining, Staining, Control, Immunostaining, Injection, Expressing

    Figure 12. Electron micrographs of ultrathin sections in the liver from animals of (A) the control group showing normal architecture of the hepatic tissues. The nuclei (N) appeared spherical with regular outlines with a small amount of heterochromatin in the peripheral regions and a large central amount of euchromatin and prominent nucleolus. The cytoplasm of the hepatocytes contains abundant mitochondria (Arrow) with well-developed cristae and the rough endoplasmic reticulum (RER) consists of closely packed parallel and flattened cisternae (Arrowhead); (B,C) methotrexate- treated group showing shrunken irregular nucleus with dispersed chromatin (N) and reduced number of the mitochondria with disrupted cristae (Arrow). The cisternae of the rough endoplasmic reticulum (RER) of the hepatocytes are fragmented (Arrowhead) with extensive fat droplets (F) and marked cytoplasmic vacuolation (V); (D) methotrexate group treated with a small dose of perindopril revealing irregular nucleus with preserved nucleolus (N). There is a mild increase in the number of the viable mitochondria with mild disrupted cristae (Arrow), partly preserved cisternae of the rough endoplasmic reticulum (Arrowhead), and small number of fat droplets could be observed (F); (E) methotrexate group treated with a moderate dose of perindopril exhibiting a spherical nucleus with regular wall and preserved nucleolus (N). There is moderate increase in the number of the mitochondria with mild disrupted cristae (Arrow) with mild disruption and wide separation of the cisternae of the rough endoplasmic reticulum (Arrowhead); (F) methotrexate group treated with a large dose of perindopril showing a normal spherical nucleus with intact regular walls and preserved nucleolus (N). The mitochondria are abundant with preserved cristae (Arrow) and the rough endoplasmic reticulum cisternae appear nearly normal with mild dilatation (Arrowhead).

    Journal: Pharmaceuticals

    Article Title: Repositioning Perindopril for Mitigation of Methotrexate-Induced Hepatotoxicity in Rats

    doi: 10.3390/ph18030358

    Figure Lengend Snippet: Figure 12. Electron micrographs of ultrathin sections in the liver from animals of (A) the control group showing normal architecture of the hepatic tissues. The nuclei (N) appeared spherical with regular outlines with a small amount of heterochromatin in the peripheral regions and a large central amount of euchromatin and prominent nucleolus. The cytoplasm of the hepatocytes contains abundant mitochondria (Arrow) with well-developed cristae and the rough endoplasmic reticulum (RER) consists of closely packed parallel and flattened cisternae (Arrowhead); (B,C) methotrexate- treated group showing shrunken irregular nucleus with dispersed chromatin (N) and reduced number of the mitochondria with disrupted cristae (Arrow). The cisternae of the rough endoplasmic reticulum (RER) of the hepatocytes are fragmented (Arrowhead) with extensive fat droplets (F) and marked cytoplasmic vacuolation (V); (D) methotrexate group treated with a small dose of perindopril revealing irregular nucleus with preserved nucleolus (N). There is a mild increase in the number of the viable mitochondria with mild disrupted cristae (Arrow), partly preserved cisternae of the rough endoplasmic reticulum (Arrowhead), and small number of fat droplets could be observed (F); (E) methotrexate group treated with a moderate dose of perindopril exhibiting a spherical nucleus with regular wall and preserved nucleolus (N). There is moderate increase in the number of the mitochondria with mild disrupted cristae (Arrow) with mild disruption and wide separation of the cisternae of the rough endoplasmic reticulum (Arrowhead); (F) methotrexate group treated with a large dose of perindopril showing a normal spherical nucleus with intact regular walls and preserved nucleolus (N). The mitochondria are abundant with preserved cristae (Arrow) and the rough endoplasmic reticulum cisternae appear nearly normal with mild dilatation (Arrowhead).

    Article Snippet: Perindopril powder was supplied by Santa Cruz Biotechnology, Inc., Dallas, TX, USA (Catalog # sc205799A; CAS No. 82834-16-0).

    Techniques: Control, Disruption

    Figure 13. The mechanisms by which perindopril mitigates methotrexate-induced hepatotoxicity (This artwork was constructed using Reactome icon library and Smart Art Servier items).

    Journal: Pharmaceuticals

    Article Title: Repositioning Perindopril for Mitigation of Methotrexate-Induced Hepatotoxicity in Rats

    doi: 10.3390/ph18030358

    Figure Lengend Snippet: Figure 13. The mechanisms by which perindopril mitigates methotrexate-induced hepatotoxicity (This artwork was constructed using Reactome icon library and Smart Art Servier items).

    Article Snippet: Perindopril powder was supplied by Santa Cruz Biotechnology, Inc., Dallas, TX, USA (Catalog # sc205799A; CAS No. 82834-16-0).

    Techniques: Construct